drugset / Trial / NCT06684431
Study to Evaluate Safety and Immunogenicity of DNA Vaccine N-pVAX1 Against Crimean Congo Hemorrhagic Fever
NaSingle-groupOpen-labelPrevention
Summary
This First-in-human dose-escalation vaccine phase I study aims to evaluate safety and reactogenicity of the investigational vaccine N-pVAX1, against Crimean Congo Hemorrhagic Fever, delivered by in vivo EP given as three im doses at weeks 0, 4 and 12.
Timeline
- Start
- 2024-11-12
- Primary completion
- 2026-03-17
- Completion
- 2026-03-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | N-pVAX1 | Vaccine | 0.45 mg | Intramuscular |
| Subject | N-pVAX1 | Vaccine | 0.9 mg | Intramuscular |
| Subject | N-pVAX1 | Vaccine | 1.8 mg | Intramuscular |